SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery

Journal of Translational Medicine

Review

Cedrik M Britten¹  James M Balwit²  Lucia G Delogu³  Lisa H Butterfield⁴  Ena Wang⁵  Francesco M Marincola⁵  Davide Bedognetti⁶  Sara Tomei⁷  Bernard A Fox⁸  Thomas F Gajewski⁹  Mary L Disis^1,10 

[1] Department of Medicine, University Medical Center of the Johannes Gutenberg-University, and Ribological GmbH, Mainz, Germany, Department of Internal Medicine, University Medical Center of the Johannes Gutenberg-University, and Clinical Development, BioNTech AG, Mainz, Germany;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Department of Drug Sciences, University of Sassari, Sassari, Italy;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA;Department of Internal Medicine (DiMI), University of Genoa, and Department of Medical Oncology, National Cancer Research Institute of Genoa, Genoa, Italy;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA;Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa and Pisa University Hospital, Pisa, Italy;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Section of Hematology/Oncology, Department of Pathology and Department of Medicine, University of Chicago, Chicago, IL, USA;Society for Immunotherapy of Cancer, Milwaukee, WI, USA;Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle, WA, USA;

关键词: Melanoma;    Clin Oncol;    Metastatic Melanoma;    Ipilimumab;    Cancer Immunotherapy;   

DOI  :  10.1186/1479-5876-9-155

 received in 2011-08-09, accepted in 2011-09-19,  发布年份 2011

来源: Springer

【 摘 要 】

Recent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are durable, dramatically extending survival. Extensive research efforts are being made to identify and validate biomarkers that can help identify subsets of cancer patients that will benefit most from these novel immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were identified by experts in the field who are actively pursuing research in biomarker identification and validation. This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies.

【 授权许可】

CC BY   
© Bedognetti et al; licensee BioMed Central Ltd. 2011